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ABSTRACT 
Alzheimer’s disease is one of the leading causes of dementia, affecting over five million people in the 
United States. It is clinically diagnosed by the presence of amyloid plaques and hyperphosphoryated tau.  
Alzheimer’s disease patients present with memory and cognitive decline. The cumulative effects of an 
increasing elderly population and the elevation in the number of persons with diseases such as 
hypertension, diabetes and obesity, which are risk factors for Alzheimer’s disease elevated the interest in 
understanding the interrelatedness between factors of metabolic syndrome and Alzheimer’s disease.  The 
disparity between the incidences of Alzheimer’s disease among racial groups in the United States also 
correlates with the differences in the incidence of metabolic syndrome (MetSyn) among these groups. We 
hypothesized that persons who are classified as MetSyn will also show deficits in cognition, carotid blood 
flow and above normal levels of IL-6 and C-reactive protein.  We believe that the amalgamation of risk 
factors associated with MetSyn might offer an explanation for the differential occurrence of Alzheimer’s 
disease in ethnic minority populations in the United States.  The study has enrolled 15 participants from 
the community.  Of the 15 participants there are 5 males and 10 females between the ages of 19 and 62, 5 of 
the participants have two or three risk factors for MetSyn and 7 are members of a minority population.  
The study is divided into 2 visits; during the first visit, anthropometric measurements and a blood draw 
for the plasma analysis of interleukin-6 and C-reactive protein are taken. The second visit consisted of the 
imaging of the carotid artery and the administration of the Penn CNP neurocognitive battery. The battery 
included measures of working memory, attention, executive function and verbal learning and memory. 
The data did not show any significant difference between persons that are metabolically compromised and 
normal controls in the areas of cognitive ability and inflammatory marker concentration.  There were 
gender and racial difference in response times in the cognitive area of working memory with males having 
lower response times than females and Caucasian having lower response times than minorities, however 
the differences are not currently significant. The study continues to enroll participants, we believe that 
with a greater sample size the trends seen in gender and racial population differences will become 
significant; particularly if we are able to increase the number of persons with metabolic syndrome.  
  
